Jonathan Friedberg
@DrJFriedberg
Followers
6K
Following
2K
Statuses
2K
Lymphoma expert. Director of @WilmotCancer Rochester NY. Editor-in-Chief, Journal of Clinical Oncology @asco_pubs. Tweets and opinions are my own.
Rochester, NY
Joined November 2014
RT @JCO_ASCO: Tune in to Cancer Stories: The Art of Oncology w/ @MikkaelSekeres. Dr. Kathryn Cappell discusses balancing patient protection…
0
6
0
RT @URMed_GCH: At this morning's annual Department of Pediatrics breakfast, David Korones, MD, hematologist-oncologist and director of the…
0
4
0
Fantastic news for @WilmotCancer; congratulations to Dr Guercio
Please join BCAN in congratulating the recipients of our 2024 Career Development Award, @anglayteng of @Stanford and @BrendanGuercio of @wilmotcancer. Both Drs. Ang and Guercio presented outstanding proposals that you can learn more about here:
0
2
12
CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling: This novel CAR-T construct leverages T-cell potency through rational design. The preliminary findings in this trial should lead to future studies across a variety of malignancies. @JCO_ASCO
0
0
2
CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients. Ongoin @SWOG S1925 trial evaluates early venetoclax-based treatment for high risk patients. @JCO_ASCO @DebbieMStephens
2
5
37
Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: PROs should be reported alongside surrogate outcomes to provide a complete picture of how a new therapy affects patients' lives. @JCO_ASCO
1
6
26
The next frontier: Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy @JCO_ASCO
0
1
2
Excellent commentary from @DrLaCasce on Targeting CD30 in Diffuse Large B-Cell Lymphoma in the growing landscape of options for relapsed disease. @JCO_ASCO
0
4
24
Pleased that our @SWOG S1826 trial (Nivolumab+AVD in advanced stage classic Hodgkin lymphoma) made the @NEJM 2024 Notable Article collection; a testimony to everyone involved in this impactful trial (particularly the patients who participated).
This year's edition of our annual Notable Articles collection, selected by NEJM editors, showcases the most significant contributions to clinical medicine and patient care. Download the collection:
1
3
34
RT @NicoGagelmann: Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma - simple: new standard of care - longer PFS than brentuximab…
0
7
0
These results demonstrate that DD-cxdl represents a therapeutic option for patients with R/R CTCL and led to FDA approval. Future studies should explore biomarkers with a goal to enable a precision approach to treatment. @JCO_ASCO
0
0
3
RT @WilmotCancer: Our teams have been spreading holiday cheer all week. We wish you happy holidays! 🎁
0
1
0
RT @WilmotCancer: Did you know Wilmot has a magazine? Dialogue has been published since 1997 - meaning it's been part of Wilmot for about h…
0
1
0
RT @WilmotCancer: As 2024 wraps up, we have to take a moment to that this year, community groups have raised and donated $300K+ to Wilmot C…
0
1
0
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis: a sobering but still optimistic assessment. @JCO_ASCO
0
0
3
Caring for the Family Caregiver in Oncology: this issue has particular resonance during the holiday season. @JCO_ASCO
0
1
6
Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia @dbranderMD @JCO_ASCO
0
3
5
The safety and high activity of N-AVD will lead to a new standard of care for most older patients with Hodgkin lymphoma if confirmed by longer follow-up of S1826; frail patients ineligible for anthracyclines require alternative approaches. @JCO_ASCO
0
10
38
We @WilmotCancer enjoy great collaborations with our colleagues @RoswellPark as we work together in the common fight against cancer, and appreciate support of @RepJoeMorelle
The researchers and doctors at @RoswellPark are some of the best in the world; helping provide cutting-edge support and resources for those battling cancer. Grateful to meet with their CEO, Dr. Candace Johnson, and discuss their ongoing work with @WilmotCancer and more.
0
2
9